No previous study has calculated the dose-conversion ratios in patients undergoing opioid rotation from a continuous intravenous infusion of morphine hydrochloride (continuous intravenous morphine) to orally administered oxycodone sustained-release tablets, frequently used clinically. We retrospectively estimated the dose-conversion ratios in 24 patients with gastrointestinal cancer who underwent opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets from October 2003 to October 2008. All patients met both of the following conditions on at least 3 consecutive days during the 10 days after rotation: 1) the basic dose of oxycodone sustained-release tablets (basic dose) was unchanged; and 2) the difference in the daily number of rescue doses was 1 or less as compared with immediately before rotation. The dose-conversion ratios were calculated by regression line analysis from the relation between "the basic dose of continuous intravenous morphine immediately before opioid rotation" and "the basic dose of oxycodone sustained-release tablets after opioid rotation." The following regression equation was obtained: Y＝ 1.736X -6.484, r 2 ＝0.956, indicating a strong correlation. The dose-conversion ratio calculated from the regression equation was 1:1.7. This result is consistent with the dose-conversion ratios of 1:1.3 to 1:2.0 for continuous intravenous morphine:oxycodone sustained-release tablets. It is important to emphasize that the dose-conversion ratio in our study was directly calculated from actual clinical data.
Introduction
Recently, the concept of "opioid rotation" has been proposed. The concept of "opioid rotation" is de ned as "treatment with the same opioid by an alternative route or with an alternative opioid administered by the same route when pain is relieved inadequately by opioid analgesics given in a dose that causes intolerable side effects despite routine measures to control them." Other reasons for opioid rotation include inadequate analgesia even after increasing the dose or inability to give a drug orally 1) .
At the time of opioid rotation, changes in the type of opioid, dosage form, or route of administration necessitate dose adjustment to obtain a similar level of analgesic ef cacy. It is therefore necessary to establish dose equivalency among different opioid preparations, and dose-conversion ratios for various preparations have been reported 2～16) . To our knowledge, however, no study has calculated dose-conversion ratios in patients undergoing opioid rotation from a continuous intravenous infusion of morphine hydrochloride (continuous in-Vol.38，No.3（2012） travenous morphine) to orally administered oxycodone sustained-release tablets, a frequently used pattern of opioid rotation clinically 17) . We therefore studied dose-conversion ratios in patients who underwent opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets. 
Methods

Study patients
Study Variables
On the basis of medical records, we studied the 
Calculation of dose-conversion ratios
Discussion
To our knowledge, no previous study has directly calculated dose-conversion ratios in patients undergoing opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets. Clinically, dose-conversion ratios have been estimated to be 3:2 for rotation from oral morphine to oxycodone sustained-release tablets 3) , and between 2:1 and 3:1 for rotation from oral morphine to intravenous morphine 4～5) .
On the basis of these data, a dose-conversion ratio between 1:1.3 and 1:2 has been used for rotation from intravenous morphine to oxycodone sustained-release tablets.
The bioavailability of morphine ranges from 20％ to 40％ 4～5) . This wide variation is attributed to the pharmacokinetic properties of morphine.
Given the pharmacokinetic parameters of mor- .
Oxycodone sustained-release tablets are an oral preparation that undergoes hepatic metabolism.
Given the pharmacokinetic parameters of oxyco- The World Health Organization three-step analgesic ladder recommends the use of non-opioid analgesics at any stage 21) . In our study, analgesics other than opioids were concurrently used in only 7 of 24 patients. However, the reasons for not using non-opioid analgesics are unknown, and further studies are thus required.
Our regression analysis showed that the doseconversion ratio in patients who underwent opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets, which is widely used clinically, was 1:1.7. This result is consistent with the dose-conversion ratios of 1:1.3 to 1:2.0 for continuous intravenous morphine:
oxycodone sustained-release tablets, estimated on the basis of dose-conversion ratios of 3:2 for oral morphine:oxycodone sustained-release tablets 3) and of 2:1 to 3:1 for oral morphine:continuous intravenous morphine 4～5) . It is important to emphasize that the dose-conversion ratio in our study was directly calculated from actual clinical data.
Oral morphine preparations and oxycodone sustained-release tablets are available as potent opioid sustained-release oral preparations in Japan. When opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets is performed, the dose-conversion ratio appears to be minimally affected by uctuations in pharmacokinetics, but this should be con rmed in further studies. The use of our results for converting the dose of continuous intravenous morphine to that of oxycodone sustained-release tablets is expected to facilitate prompt, appropriate dose adjustment in patients with cancer pain who undergo opioid rotation from continuous intravenous morphine to oxycodone sustained-release tablets, thereby improving their quality of life.
